

**Washington State Pharmacy and Therapeutics Committee
Drug Utilization Review Board
Date: October 16, 2019
Time: 9 a.m. to 4 p.m.
Port of Seattle “International A” Conference Room
Seattle-Tacoma International Airport
17801 International Blvd., Seattle, WA 98158**

9 a.m.	Welcome & Introductions Committee votes on vice-chair Pharmacy & Therapeutics Committee Convenes	Lisa Chew, Committee Chair
9:10 a.m.	PCSK9 Inhibitors- full report (Antihyperlipidemics : PCSK-9 Inhibitors) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Curtis Harrod, DERP
9:50 a.m.	ADHD- surveillance report Stimulants and Related Agents (ADHD / Narcolepsy : Stimulants and Non-stimulants) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Beth Shaw, DERP Umang Patel, Magella
10:20 a.m.	Break	All
10:30 a.m.	Biologic Drugs for Asthma and Urticaria- surveillance report Immune Modulators, Asthma (Asthma and Copd Agents : Monoclonal Antibodies) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Shannon Robalino, DERP Umang Patel, Magellan
11:05 a.m.	Atopic Dermatitis Agents- surveillance report Immunomodulators, Atopic Dermatitis (Dermatologies : Atopic Dermatitis Agents) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Beth Shaw, DERP Umang Patel, Magellan
11:35 a.m.	Pharmacy & Therapeutics Committee Adjourns Drug Utilization Review (DUR) Board Convenes	Lisa Chew, Committee Chair
11:35 a.m.	HIV Antivirals (Antivirals : HIV) Apple Health Policy <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan Donna Sullivan, HCA
12:05 p.m.	Lunch	All
12:35 p.m.	Apple Health Policies: <ul style="list-style-type: none"> • Antiasthmatic Monoclonal Antibodies : IgE-5 Antagonists, omalizumab (Xolair®) • Antiasthmatic Monoclonal Antibodies : IL-5 Agents • Dupilumab (Dupixent) • Atopic Dermatitis Agents - carisaborole, (Eucrisa™) • Atopic Dermatitis Agents – Topical Immunosuppressives • ADHD / Narcolepsy – Stimulants <ul style="list-style-type: none"> ○ Stakeholder input* 	Donna Sullivan, HCA

** Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby.
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions
please call Leta Evaskus at 206-521-2029.

	○ Motion	
1:35 p.m.	Opioid Policy Updates (SUPPORT Act) – Information Only	Donna Sullivan, HCA
2:05 p.m.	COPD Agents (Asthma and COPD Agents : Long Acting Muscarinic Agents; Anticholinergics; Long Acting Muscarinic Agent / Long Acting Beta Agonist Combinations; Phosphodiesterase 4 Inhibitors) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
2:20 p.m.	Break	All
2:30 p.m.	Bronchodilators (Asthma and COPD Agents: Beta Agonists – Short Acting; Oral; Long Acting) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
2:45 p.m.	Glucocorticoids, Inhaled (Asthma and COPD Agents: Inhaled Corticosteroids & ICS Combinations) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
3 p.m.	Dermatologics: Antipsoriatics – Orals Apple Health Policy <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan Donna Sullivan, HCA
3:15 p.m.	Dermatologics: Antipsoriatics – Topicals <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
3:30 p.m.	Immunomodulators, Topical (Dermatologics : Keralytic / Antimitotic Agents; Immunomodulating Agents – Topical; Agents for External Genital and Perianal Warts) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
3:45 p.m.	Dermatologics: Emollients <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
4 p.m.	Drug Utilization Review Board Adjourns	Lisa Chew, Committee Chair

** Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.